MoneyWorks4Me

Cipla's arm completes acquisition of stake in Wellthy Therapeutics

11 Mar 2019 Evaluate

Cipla's wholly owned subsidiary -- Goldencross Pharma has completed the closing of Wellthy Therapeutics, transaction representing an acquisition of 11.71% stake in Wellthy on fully diluted basis on March 08, 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Peers
Company Name CMP
Sun Pharma. Inds. 1844.00
Dr. Reddys Labs. 1235.60
Cipla 1389.90
Lupin 2076.30
Zydus Lifesciences 1217.00
View more..